REMICADE Market Drug Insight and Market Forecast - 2032

“REMICADE Market Drug Insight and Market Forecast - 2032” report provides comprehensive insights about REMICADE for Ulcerative Colitis (UC) in the seven major markets. A detailed picture of the REMICADE for ulcerative colitis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the REMICADE for ulcerative colitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the REMICADE market forecast analysis for ulcerative colitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ulcerative colitis.

Drug Summary

REMICADE is a product developed by Janssen Biotech (formerly known as Centocor), a subsidiary of Johnson & Johnson. The active ingredient in REMICADE is a chimeric IgG1κ monoclonal antibody (composed of human constant and murine variable regions) specific for human tumor necrosis factor-alpha (TNFα). It has a molecular weight of approximately 149.1 kDa. Infliximab is produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps that includes measures to inactivate and remove viruses, reducing the effects of a substance in the body that can cause inflammation.

Dosage
Dosage in adult UC
The recommended dosage of REMICADE is 5 mg/kg given as an intravenous induction regimen at 0, 2, and 6 weeks, followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adult patients with moderately to severely active UC.

Dosage in pediatric UC
The recommended dosage of REMICADE for pediatric patients 6 years and older with moderately to severely active UC is 5 mg/kg given as an intravenous induction regimen at 0, 2, and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks.

Mechanism of Action

Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibits the binding of TNFα with its receptors. Infliximab does not neutralize TNFβ (lymphotoxin-α), a related cytokine that utilizes the same receptors as TNFα. Biological activities attributed to TNFα include induction of pro-inflammatory cytokines such as interleukins (IL) 1 and 6, enhancement of leukocyte migration by increasing endothelial layer permeability and expression of adhesion molecules by endothelial cells and leukocytes, activation of neutrophil and eosinophil functional activity, induction of acute-phase reactants and other liver proteins, as well as tissue degrading enzymes produced by synoviocytes and/or chondrocytes. Cells expressing transmembrane TNFα bound by infliximab can be lysed in vitro or in vivo. Infliximab inhibits the functional activity of TNFα in a wide variety of in vitro bioassays utilizing human fibroblasts, endothelial cells, neutrophils, B and T-lymphocytes, and epithelial cells. The relationship of these biological response markers to the mechanism(s) by which REMICADE exerts its clinical effects is unknown. Anti-TNFα antibodies reduce disease activity in the cotton-top tamarin colitis model and decrease synovitis and joint erosions in a murine model of collagen-induced arthritis. Infliximab prevents disease in transgenic mice that develop polyarthritis due to the constitutive expression of human TNFα, and when administered after disease onset, it allows eroded joints to heal.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the REMICADE description, mechanism of action, dosage and administration, research and development activities in ulcerative colitis.
• Elaborated details on REMICADE regulatory milestones and other development activities have been provided in this report.
• The report also highlights the REMICADE research and development activities in ulcerative colitis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around REMICADE.
• The report contains forecasted sales of for ulcerative colitis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ulcerative colitis.
• The report also features the SWOT analysis with analyst views for REMICADE in ulcerative colitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

REMICADE Analytical Perspective

In-depth REMICADE Market Assessment

This report provides a detailed market assessment of REMICADE for ulcerative colitis in the seven major markets, i.e., United States, EU4 (Germany, France, Italy, Spain), the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

REMICADE Clinical Assessment

The report provides the clinical trials information of REMICADE for ulcerative colitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for ulcerative colitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence REMICADE dominance.
• Other emerging products for ulcerative colitis are expected to give tough market competition to REMICADE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of REMICADE in ulcerative colitis.
• This in-depth analysis of the forecasted sales data of REMICADE from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the REMICADE in ulcerative colitis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of REMICADE?
• What is the clinical trial status of the study related to REMICADE in ulcerative colitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the REMICADE development?
• What are the key designations that have been granted to REMICADE for ulcerative colitis?
• What is the forecasted market scenario of REMICADE for ulcerative colitis?
• What are the forecasted sales of REMICADE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to REMICADE for ulcerative colitis?
• Which are the late-stage emerging therapies under development for the treatment of ulcerative colitis?

This product will be delivered within 2 business days.